Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Friend? IXICO Seeks To Boost MS Drug Sales With Brain Health Tech

This article was originally published in Clinica

Executive Summary

IXICO has struck a partnership with a major pharma player to help improve clinical outcomes of the latter’s blockbuster drug for multiple sclerosis – which will hopefully lead to increased sales – by adding the use of IXICO’s Assessa digital brain health monitoring technology to better manage a serious and potentially fatal side effect of the therapy.

You may also be interested in...



Brain-Health Company IXICO Ready To Seize Pharma's Digital Health Opportunities

Brain-health company IXICO is ready to seize pharma's digital health opportunities by expanding into the companion digital health product sector. Last year the company partnered with Biogen to pilot its digital platform Assessa with the drug TYSABRI.

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Topics

UsernamePublicRestriction

Register

MT102919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel